Literature DB >> 11260151

Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose inhaled steroids.

D C Grootendorst1, S E Dahlén, J W Van Den Bos, E J Duiverman, M Veselic-Charvat, E J Vrijlandt, S O'Sullivan, M Kumlin, P J Sterk, A C Roldaan.   

Abstract

Some patients with severe asthma cannot be controlled with high doses of inhaled steroids (ICS), which may be related to ongoing environmental allergen exposure. We investigated whether 10 weeks of high altitude allergen avoidance leads to sustained benefits regarding clinical and inflammatory markers of disease control in adolescents with persistent asthma despite treatment with high dose ICS. Eighteen atopic asthmatic adolescents (12-18 yr, 500-2000 microg ICS daily) with established house dust mite allergy, participated in a parallel-group study. Quality of life (PAQL), lung function, bronchial hyperresponsiveness (BHR) to adenosine and histamine, induced sputum and urine samples were collected repeatedly from 10 patients during a 10-week admission period to the Swiss Alps (alt. 1560 m) and at 6 weeks after return to sea level. Results were compared with those in eight patients, studied in their home environment at sea level for a similar time period. Throughout the study, asthma medication remained unchanged in both groups. During admission to high altitude, PAQL, lung function, BHR to adenosine and histamine, and urinary levels of eosinophil protein X (U-EPX), leukotriene E4 (U-LTE4) and 9alpha11beta prostaglandin F2 (U-9alpha11beta PGF2) improved significantly (P < 0.05), with a similar tendency for sputum eosinophils (P < 0.07). Furthermore, the changes in PAQL and BHR to adenosine and histamine were greater in the altitude than in the control group (P < 0.05). At 6 weeks after renewed allergen exposure at sea level, the improvements in PAQL (P < 0.05), BHR to adenosine (P < 0.07) and histamine (P < 0.05), as well as U-EPX (P < 0.05) and U-LTE4 (P < 0.05) were maintained. A short period of high altitude allergen avoidance, on top of regular treatment with ICS and long-acting beta2-agonists, results in improvement of asthma, as assessed by clinical and inflammatory markers of disease severity. These findings indicate that short-term, rigorous allergen avoidance can improve the long-term control of severe asthma over and above what can be achieved even by high doses of inhaled steroids.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11260151     DOI: 10.1046/j.1365-2222.2001.01022.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  25 in total

1.  Identification of relevant ICF categories for indication, intervention planning and evaluation of health resort programs: a Delphi exercise.

Authors:  E Morita; M Weigl; A Schuh; G Stucki
Journal:  Int J Biometeorol       Date:  2005-11-18       Impact factor: 3.787

2.  Dust mite control measures don't help asthma patients.

Authors:  Sarah-Anne Schumann; John Hickner
Journal:  J Fam Pract       Date:  2008-12       Impact factor: 0.493

3.  Lung disease at high altitude.

Authors:  Joshua O Stream; Andrew M Luks; Colin K Grissom
Journal:  Expert Rev Respir Med       Date:  2009-12       Impact factor: 3.772

Review 4.  Mite immunotherapy.

Authors:  Enrique Fernández-Caldas; Victor Iraola; Manuel Boquete; Antonio Nieto; Miguel Casanovas
Journal:  Curr Allergy Asthma Rep       Date:  2006-09       Impact factor: 4.806

Review 5.  The immunology of asthma: Asthma phenotypes and their implications for personalized treatment.

Authors:  Larry Borish
Journal:  Ann Allergy Asthma Immunol       Date:  2016-08       Impact factor: 6.347

Review 6.  Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma.

Authors:  Francine M Ducharme; Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

7.  Macrophage Phagocytosis and Allergen Avoidance in Children With Asthma.

Authors:  Neeta Kulkarni; Ahmad Kantar; Silvia Costella; Vincenzo Ragazzo; Giorgio Piacentini; Attilio Boner; Christopher O'Callaghan
Journal:  Front Pediatr       Date:  2018-08-02       Impact factor: 3.418

Review 8.  Does climate therapy at moderate altitudes improve pulmonary function in asthma patients? A systematic review.

Authors:  Tanja Massimo; Cornelia Blank; Barbara Strasser; Wolfgang Schobersberger
Journal:  Sleep Breath       Date:  2013-06-18       Impact factor: 2.816

Review 9.  Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease.

Authors:  R Polosa; S Rorke; S T Holgate
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

Review 10.  Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children.

Authors:  Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.